Instil Bio, Inc.

NASDAQ:TIL

Biotechnology

Healthcare
$7.45 +0.13%

+$0.01 today

Market cap
$50.53M
Beta
1.91
P/E (TTM)
-1.1
EPS (TTM)
-$6.99
52W Low $5.67High $33.83

Volume 0.02M

Average 0.03M

TIL Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Instil Bio, Inc.NASDAQ: TIL

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt rises 12.4% from a year ago

Net debt stood at $80.16M at the end of Q1 FY2026, up 12.4% from a year earlier and up 2.1% from the prior quarter. Over 3 fiscal years it compounded at +29.5% a year.

Context

  • Net debt amounted to 40.0% of total assets at the end of Q1 FY2026, up 10.0 pp from a year earlier.
  • Net debt increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +12.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$80.16M+2.1% QoQ
Last fiscal yearDec 2025
$78.54M+0.6% YoY
Year agoMar 2025
$71.3M+12.4% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.4%——
1 year+0.6%——
3-year CAGR+29.5%——
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
78.54M USD
Year-over-year change
+0.6%

Net Debt vs competitors

How TIL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +12.4% is the 7th highest of 9, against a peer median of +70.9%.
  • Net debt amounts to 40.0% of total assets for TIL, versus a peer median of 28.2%.
TIL Competitors
Net Debt for TIL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TILInstil Bio, Inc.Mar 2026$80.16M USD+12.4%+29.5%40.0%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$6.72M USD+2809.5%-5.6%2.7%
PLRXPliant Therapeutics, Inc.Mar 2026$6.59M USD+120.8%—3.3%
ONCYOncolytics Biotech Inc.Mar 2026-CA$4.99M CAD+65.1%—61.1%
IFRXInflaRx N.V.Mar 2026-€14.19M EUR+69.5%—29.0%
MGNXMacroGenics, Inc.Mar 2026-$30.01M USD+72.2%—13.8%
WHWKWhitehawk Therapeutics IncMar 2026-$34.79M USD+84.7%—27.3%
STTKShattuck Labs, Inc.Mar 2026-$87.53M USD-51.7%—85.7%
SRZNSurrozen, Inc.Mar 2026-$100.13M USD-6.9%—83.0%
Peer median (excluding TIL) —+70.9%-5.6%28.2%

Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents37.59M43.72M9.2M8.81M6.64M
Short-term Investments416.51M217.2M141.16M104.51M69.49M
Net Receivables0000848K
Inventory00000
Other Current Assets08.46M1.5M1.83M112.41M
Total Current Assets464.02M269.38M160.76M124.47M191.43M
Property, Plant & Equipment (Net)122M209.34M141.07M130.34M364K
Goodwill5.72M0000
Intangible Assets10.1M0000
Long-term Investments0023.16M00
Tax Assets00000
Other Non-current Assets8.14M3.41M639K8.76M11.73M
Total Non-current Assets145.96M212.75M164.87M139.1M12.09M
Total Assets609.98M482.13M325.63M263.57M203.52M
Account Payables5.57M2.36M1.21M659K779K
Short-term Debt00000
Tax Payables524K0000
Deferred Revenue00000
Other Current Liabilities13.66M4.23M1.22M2.07M2.52M
Total Current Liabilities41.36M32.79M10.56M7.9M4.84M
Long-term Debt072.35M81.43M84.19M84.81M
Deferred Tax Liabilities2.43M0000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities11M8.21M4.94M1.03M8K
Total Non-current Liabilities13.43M85.74M89.24M86.24M84.81M
Total Liabilities54.78M118.52M99.8M94.13M89.66M
Common Stock00000
Retained Earnings(201.72M)(424.89M)(580.98M)(655.12M)(726.49M)
Accumulated OCI(87K)(493K)(348K)(228K)(583K)
Other Stockholders Equity000(0)0
Minority Interest00000
Total Equity555.2M363.61M225.83M169.44M113.87M
Total Debt079.9M86.05M86.89M85.18M
Net Debt(37.59M)36.19M76.86M78.08M78.54M

Instil Bio, Inc.

NASDAQ:TIL

Intrinsic Alpha fair value

Locked

Current Price

$7.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.